| |
Learning Center
Hemostasis Happenings
Sunday, November 1, 2009
HEMOSTATIS HAPPENINGS NOVEMBER 2009
EVENT: 'UK NEQAS POINT OF CARE INR TESTING MEETING'
SEPSIS 2009 PROGRAMNear Patient/Point of Care Testing for Monitoring oral anticoagulant control.
Mercue St Paul's Hotel, 119 Norfolk Street, Sheffield, S1 2JE
1300-1630 - Sepsis 2009 Pre-Meeting - November 11th
Sepsis Research in The Netherlands - Program Chair: Marcus J. Schultz
1300 Welcome Marcus Schultz
1305-1325 Prevalence and Incidence of Severe Sepsis in Dutch ICU Jan Bakker
1325-1345 The Influence of Volume and ICU Organization on Hospital Mortality in Patients Admitted with Severe Sepsis Evert de Johge
1345-1405 Corticosteroids in Septic Shock Johan Groenveveld
1405-1425 Safety of Drotrecogin Alfa (Activated) Therapy Pierre Francois Laterre
1425-1445 The Impact of Severe Sepsis on Health-related Quality of Life Peter Spronk
1445-1500 Break
1500-1520 Alkaline Phosphatase Treatment in Severe Sepsis or Septic Shock Patients Peter Pickkers
1520-1540 Reducing Metabolism in Acute Lung Injury Nicole Juffermans
1540-1600 Hypothermia for (Severe) Sepsis Kees Polderman
1600-1620 Anticoagulant Therapies in Acute Lung Injury Marcus Schultz
1620 Discussion, Summary and Close Marcus Schultz
1210-1330
1330-1730 - Afternoon Session - Coagulation in Sepsis and Critical Illness -
Chair: Mitchell Fink
1330-1355 Tissue Factor and Protease Activated Receptors in Sepsis Steven Opal, Providence, USA
1355-1420 The Protein C System in Sepsis Tom van der Poll, Amsterdam, the Netherlands
1420-1445 The Vascular Endothelium in Sepsis Victor van Hinsbergh, Amsterdam, the Netherlands
1445-1515 Break
1515-1540 Intrapulmonary Anticoagulation in Lung Injury Marcus Schultz, Amsterdam, the Netherlands
1540-1605 Genetics, Coagulation and Sepsis Jean-Paul Mira, Paris, France
1605-1630 Roundtable Discussion - What should be be doing differently to manage coagulation in sepsis?
1630-1710 Keynote Lecture: Clinical Implications of Coagulation and Bleeding Disorders in the ICU Marcel Levi, Amsterdam, the Netherlands
1710-1900 Poster Viewing
1340-1640 - Afternoon Session - Update on Clinical Trials in Sepsis -
Chairs: Tom van der Poll & Stephen Lowry
1340-1355 Toll-Like Receptor-4 Antagonist in the Treatment of Sepsis Steven Opal, Pawtucket, USA
1355-1410 TFPI trials in CAP and Sepsis Richard Wunderink, Chicago, USA
1410-1425 EGDT and Other "Bundle" Trials in Sepsis Derek Angus, PIttsburgh, USA
1425-1440 Thrombomodulin in Sepsis Jean-Louis Vincent, Brussels, Belgium
November 14th
0830-1245 - Morning Session - Endocrine Dysfunction in Sepsis -
Chairs: John Marshall & Jean-Paul Mira
0830-0910 Keynote Lecture: Endocrine Function in Sepsis and Shock Djillali Annane, Garches, France
0910-0930 The Metabolic Response to Sepsis Stephen Lowry, New Brunswick, USA
0930-0950 The Thyroid in Sepsis Antonio Bianco, Miami, USA
0950-1010 Sex Hormones and Sepsis Irshad Chaudry, Birmingham, USA
1010-1040 Break
1040-1100 Calcium Regulation in Sepsis Matthew Rosengart, Pittsburgh, USA
1100-1120 Is Sepsis a Vassopressin Deficiency State? Konrad Reinhart, Jena, Germany
1120-1140 Roundtable Discussion - Is hormone replacement therapy a real concept in critical illness?
1140-1240 Best Abstract awards
1240-1300 Closing Remarks
California Blood Bank Society
Transfusion Medicine Regional Seminar
Presented by the Medical Technologists Committee
November 14, 2009
UCSF Medical Center, Room N-217
505 Parnassus Avenue
San Francisco, CA
Kaiser Imperial Satellite Office, Room IS17
12200 Bellflower Blvd.
2:30-3:30 Coagulation for Blood Bankers
James Huang, MD, Associate Clinical Professor; Director, Pediatric Hematology, UCSF School of Medicine
Objective: Identify indications for using various blood products in the treatment of coagulation disorders.
Mr. Scott Diamond, University of Pennsylvania
Wednesday, November 18, 2009, 12:10 - 1:15 pm, Room 210 Hallowell Building, CG624EAbstract
The dynamics of thrombosis depend on prevailing hemodynamics in conjunction with biochemical determinants at the injury site (i.e. tissue factor, vWF, and collagen) along with prevailing biological attributes of the flowing blood. Fluid flow affects: platelet fluxes to the wall, the time available to form bonds, force loading of bonds, cellular deformation, endothelial metabolism, and removal of reactive species created during thrombotic events. We have deployed a variety of techniques in microfluidics and combinatorial high throughput phenotyping of platelet and coagulation function to drive hierarchical Systems Biology models of platelet metabolism and thrombus buildup under flow.
Cardiovascular Anesthesia Review - Las Vegas, Nevada
11.16.2009 - 11.20.2009
PROGRAM SCHEDULE
*
CARDIOVASCULAR ANESTHESIA REVIEW
November 17-20, 2009
Friday, November 20
0730 Registration - Mandatory Sign In - Continental Breakfast
0745 Anesthesia for Thoracic Aortic Disease J.Augoustides
0845 Avoiding Major Postoperative Complications after CV Surgery J.Augoustides
0945 Break
1000 Blood, Coagulation, and Coagulopathies with CV Surgery E.Lobato
1100 Pacemakers, AICDs, and other Stimulators E.Lobato
1200 Panel Discussion: Uncommon Cardiac Dieases: What do I do Now? J.Augoustides, J.Kaplan, E.Lobato
1300 Adjourn 20 CME I / 20 CEC
Donna Castellone
|
|
About the Author
Donna Castellone,
MS, MT(ASCP)SH
View Complete Profile
Links
Previous Posts
Archives
|
|
